Quoin Pharmaceuticals Ltd. (QNRX) rose 21.15% to $9.99, up $1.74, after announcing that its topical delivery platforms achieved target rapamycin loadings of 4% w/w in a lotion and 5% w/w in a dermal patch.
The company plans to manufacture clinical trial and stability batches in the fourth quarter of 2025 and initiate clinical testing in 1H 2026 for indications including microcystic lymphatic malformations and venous malformations, conditions currently lacking FDA-approved treatments.
On the day of the announcement, QNRX experienced unusually heavy trading volume as investors reacted to the data. The stock's 52-week range is $2.65 - $9.99.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.